Market closed
Ultragenyx Pharmaceutical/$RARE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Ticker
$RARE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,276
Website
RARE Metrics
BasicAdvanced
$4B
-
-$6.43
0.58
-
Price and volume
Market cap
$4B
Beta
0.58
52-week high
$58.73
52-week low
$37.02
Average daily volume
1M
Financial strength
Current ratio
2.806
Quick ratio
2.465
Long term debt to equity
241.175
Total debt to equity
214.269
Interest coverage (TTM)
-8.26%
Management effectiveness
Return on assets (TTM)
-24.12%
Return on equity (TTM)
-289.98%
Valuation
Price to revenue (TTM)
7.194
Price to book
11.51
Price to tangible book (TTM)
29.03
Price to free cash flow (TTM)
-8.556
Growth
Revenue change (TTM)
27.44%
Earnings per share change (TTM)
-28.34%
3-year revenue growth (CAGR)
13.29%
3-year earnings per share growth (CAGR)
6.52%
What the Analysts think about RARE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ultragenyx Pharmaceutical stock.
RARE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RARE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RARE News
AllArticlesVideos
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
Benzinga·2 weeks ago
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ultragenyx Pharmaceutical stock?
Ultragenyx Pharmaceutical (RARE) has a market cap of $4B as of January 29, 2025.
What is the P/E ratio for Ultragenyx Pharmaceutical stock?
The price to earnings (P/E) ratio for Ultragenyx Pharmaceutical (RARE) stock is 0 as of January 29, 2025.
Does Ultragenyx Pharmaceutical stock pay dividends?
No, Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders as of January 29, 2025.
When is the next Ultragenyx Pharmaceutical dividend payment date?
Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders.
What is the beta indicator for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.